KDx Diagnostics, Cardiff University, Cardiff and Vale University Health Board and Cellpath announce

CAMPBELL, Calif. and CARDIFF, Wales, May 18, 2021 /PRNewswire/ — KDx Diagnostics, Inc. (KDx), Clinical Innovation Accelerator (CIA), Cardiff University, Cardiff and Vale University Health Board C&VUHB) and CellPath, announced today a partnership to develop a non-invasive urine test for suspected bladder cancer patients through the Accelerate programme.  KDx Diagnostics Inc., located in Campbell, CA, USA, has developed a non-invasive urine test, URO17® that has shown high accuracy detection of bladder cancer in multiple independent studies, and will provide all technical components for the project… Read More